Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370265 | 1.00 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL4551781 | 1.00 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL8716290 | 0.88 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL30942655 | 0.88 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6575309 | 0.88 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL5620372 | 0.83 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL22271652 | 0.83 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1948741 | 0.83 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL7515399 | 0.83 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2246074 | 0.82 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441679-B2 | Acrylamide-substituted indane compounds and therapeutic use thereof | SANOFI (FR) | 2025-10-14 | — | — | US | disclosed |
| CN-116057042-B | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2024-10-18 | — | — | CN | disclosed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| EP-4188907-A1 | ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2023-06-07 | — | — | EP | disclosed |
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | disclosed |
| US-11312726-B2 | Thienodiazepine derivatives and application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| WO-2022023460-A1 | ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2022-02-03 | — | — | WO | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210017190-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-0552817-B1 | Milbemycin ether derivatives, their preparation and their therapeutic and agrochemical uses | SANKYO CO (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0552818-B1 | Milbemycin ether derivatives, their preparation and their therapeutic and agrochemical uses | SANKYO CO (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5604182-A | EXHIBIT ANTHELMINTIC, ACARICIDAL AND INSECTICIDAL ACTIVITIES | SANKYO COMPANY LIMITED (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0448243-B1 | Milbemycin ether derivatives, their preparation and their therapeutic and agrochemical uses | SANKYO CO (JP) | 1996-01-17 | — | — | EP | disclosed |
| US-5346918-A | Anthelmintics, acaridices, insecticides | SANKYO COMPANY LIMITED (JP) | 1994-09-13 | — | — | US | disclosed |
| EP-0552817-A2 | Milbemycin ether derivatives, their preparation and their therapeutic and agrochemical uses | Sankyo Company Limited (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0552818-A2 | Milbemycin ether derivatives, their preparation and their therapeutic and agrochemical uses | Sankyo Company Limited (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0448243-A1 | Milbemycin ether derivatives, their preparation and their therapeutic and agrochemical uses | Sankyo Company Limited (JP) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017190-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | BRD4, BRD3, BRD2 | PNMT 236/4885ADRA2A 322/4885ADRA2B 99/4885 |
| US-12441679-B2 | Acrylamide-substituted indane compounds and therapeutic use thereof | IDH2, INA, IDH3A | PNMT 158/4885ADRA2A 308/4885ADRA2B 539/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PNMT 2799/4885ADRA2A 4682/4885ADRA2B 4512/4885 |
| US-11312726-B2 | Thienodiazepine derivatives and application thereof | BRD4, BRD3, BRD2 | PNMT 236/4885ADRA2A 322/4885ADRA2B 99/4885 |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | IDH2, INA, IDH3A | PNMT 158/4885ADRA2A 308/4885ADRA2B 539/4885 |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | TRPV1, HRH2, TRPA1 | PNMT 2296/4885ADRA2A 116/4885ADRA2B 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.